MedTrace Logo

Chewing Gum in Hemodialysis Patients

NCT05241587 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-02-15

No results posted yet for this study

Summary

This study was conducted to evaluate the effect of chewing xylitol gum on thirst, dry mouth and nausea in patients undergoing haemodialysis.Patients undergoing haemodialysis often experience thirst, dry mouth and nausea.This was a prospective, non-randomized experimental study involving a control group. The study was carried out with patients undergoing haemodialysis in a private dialysis centre in the northeast of Turkey between July and December 2018. It was completed with a total of 75 patients assigned to the gum group (n=25), mouth spray group (n=25), and control group (n=25).The patients in the gum group chewed xylitol gum for 10 minutes, five times a day for six weeks. Patients in the mouth spray group used two puffs of mouth spray three times a day. No intervention was made in the control group. Data were collected with the Patient Information Form, Charlson Comorbidity Index, Visual Analogue Scale, Rhodes Index of Nausea, Vomiting and Retching, graduated tube, and pH meter. Data were evaluated with Mann-Whitney U, Pearson Chi-square, Kruskal Wallis and Friedman tests. TREND checklist for non-randomised controlled trials was followed.

Conditions

  • Mouth Dryness
  • Nausea
  • Hemodialysis Complication
  • Nurse's Role
  • Thirst

Interventions

OTHER

Gum Group:

Gum Group: Gum group patients consisted of patients who chewed "Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh". It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010).

OTHER

Mouth Spray Group:

Mouth Spray Group: The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request.

Sponsors & Collaborators

  • Didem Sarımehmet

    lead OTHER

Principal Investigators

  • Didem Sarımehmet, PhD · Karadeniz Techinical University

  • Sevilay Hintistan, PhD · Karadeniz Techinical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-03
Primary Completion
2019-05-22
Completion
2020-12-12

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05241587 on ClinicalTrials.gov